ACSL3 Promotes Hepatocellular Carcinoma Tumorigenesis and Correlates With JAK-STAT3 Signaling

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Hepatocellular carcinoma (HCC) presents a significant global health challenge with limited effective treatments.
• Aberrant lipid metabolism, particularly increased de novo lipogenesis, is a critical driver of HCC development and progression.
• The enzyme Acyl-CoA synthetase 3 (ACSL3) is implicated in HCC pathogenesis and is associated with poor patient prognosis.

Purpose of the Study:

• To investigate the role of ACSL3 in hepatocellular carcinoma (HCC).
• To explore the molecular mechanisms linking ACSL3 to HCC tumorigenesis and immune evasion.
• To evaluate ACSL3 as a potential therapeutic target and biomarker for HCC.

Main Methods:

• Comparative analysis of ACSL3 expression in vivo and ex vivo.
• Bioinformatic analyses, including Gene Set Enrichment Analysis (GSEA) and KEGG pathway analysis, were utilized.
• Exploration of correlations between ACSL3 expression and signaling pathways, lipogenic enzymes, and immune checkpoint regulators.

Main Results:

• ACSL3 expression was consistently upregulated across various HCC models.
• High ACSL3 levels correlated with the activation of the STAT3 signaling pathway and increased expression of lipogenic enzymes, indicating a positive feedback loop.
• Predictive analyses suggested a link between elevated ACSL3 and the expression of Programmed Death-Ligand 1 (PD-L1), an immune checkpoint regulator.

Conclusions:

• ACSL3 serves as a crucial biomarker for HCC prognosis and a promising therapeutic target.
• ACSL3 integrates dysregulated lipid metabolism with oncogenic signaling pathways and immune evasion mechanisms in HCC.
• Further research into ACSL3-targeted therapies is warranted for effective HCC treatment strategies.